IFN-III is selectively produced by cDC1 and predicts good clinical outcome in breast cancer
Margaux Hubert, Élisa Gobbini, Coline Couillault, Thien‐Phong Vu Manh, Anne-Claire Doffin, Justine Berthet, Céline Rodriguez, Vincent Ollion, Janice Kielbassa, Christophe Sajous, Isabelle Treilleux, Olivier Trédan, Bertrand Dubois, Marc Dalod, Nathalie Bendriss‐Vermare, Christophe Caux, Jenny Valladeau‐Guilemond
Abstract
1 microenvironment through increased production of IL-12p70, IFN-γ, and cytotoxic lymphocyte-recruiting chemokines. Last, we showed that engagement of TLR3 is a therapeutic strategy to induce IFN-III production by tumor-associated cDC1. These data provide insight into potential IFN- or cDC1-targeting antitumor therapies.
Topics & Concepts
Immune systemImmunotherapyCancer researchChemokineTumor microenvironmentDendritic cellCCR4BiologyInterferonImmunologyCytotoxic T cellMedicineChemokine receptorBiochemistryIn vitroImmunotherapy and Immune ResponsesImmune Response and InflammationT-cell and B-cell Immunology